Literature DB >> 6203365

Characteristics of basophil histamine release by neuromuscular blocking drugs in patients with anaphylactoid reactions.

E S Assem.   

Abstract

Histamine release from the basophil leucocytes of patients with apparently non-immune, anaphylactiod reactions to neuromuscular blockers ( NMB ) has been studied in vitro. Substantial release was obtained in the majority of patients with clinical reactions, with little or no release in normal subjects. The chemical specificity and selectivity varied in individual patients: each individual reacting to one agent or a particular combination of NMB drugs. The test was of considerable diagnostic and predictive value. We studied some of the characteristics of the histamine release process and the effect of certain modulators. The findings strongly suggest a non-cytotoxic secretory process requiring the presence of two quaternary ammonium groups as suggested by the rarity of release with tubocurarine; inhibition of succinyldicholine (suxamethonium)-induced histamine release by serum cholinesterase treatment, acetylcholine and tubocurarine; and the bell-shaped dose-response curve, particularly with suxamethonium. Histamine release by all NMB was completely inhibited in calcium-free medium, and markedly potentiated by deuterium oxide, a microtubule stabilizer. Both tachyphylaxis (by prior exposure to the specific agent in absence of calcium), and cross-tachyphylaxis with anti-IgE were elicited.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6203365     DOI: 10.1007/bf01973845

Source DB:  PubMed          Journal:  Agents Actions        ISSN: 0065-4299


  2 in total

1.  Detection of serum IgE antibodies that react with alcuronium and tubocurarine after life-threatening reactions to muscle-relaxant drugs.

Authors:  B A Baldo; M M Fisher
Journal:  Anaesth Intensive Care       Date:  1983-08       Impact factor: 1.669

2.  Anaphylactic-like reaction to suxamethonium.

Authors:  E S Assem; P G Frost; R D Levis
Journal:  Anaesthesia       Date:  1981-04       Impact factor: 6.955

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.